MSc, PhD in Molecular Biology, Stockholm University. Anna Junell is an experienced Clinical Project Manager with 25 years’ experience of planning, operational coordination, management, and execution of projects in pharmaceutical companies, clinical research organizations (CROs) and academia. Anna has held various roles within sponsor oversight, project management and GCP expertise at Wyeth, Pfizer, ReSearch Pharmaceutical Services/PRA (Novartis), Clintec (MSD) and and is currently a consultant at SDS Life Science, a Cytel company.
PhD in Neuroscience and Cell Biology. Linda Nord has more than 15 years of experience of the life science industry with focus on regulatory strategy and project management across the full drug development lifecycle, including acting as lead for marketing applications and post-marketing regulatory activities. Previously she has had roles within regulatory affairs at AstraZenca and Swedish Orphan Biovitrum (Sobi) and is currently a consultant at LINK Medical.
PhD in Medical Science Karolinska Institute. Johanna Apro has over 15 years of experience from medical research and the life science sector. She has held positions within quality assurance and clinical operations at Karolinska University Hospital and is currently a consultant at SDS Life Science, a Cytel company.
"Master in Pharmacy, PhD and Associate Professor in Biopharmaceutics. David Dahlgren has an academic research background focusing on pharmacokinetics and translational drug development, including in vitro, in vivo and in silico drug delivery as well as preclinical and clinical effect and toxicity studies of anti-cancer drugs. He is currently a consultant at SDS Life Science, a Cytel company.
MSc in Toxicology from Karolinska Institute, European Registered Toxicologist (ERT). Carol Björkheden has extensive experience in the nonclinical aspects of Drug Development, particularly within Regulatory Toxicology. This spans over 30 years as Global Toxicology Project Leader for several major brands at Astra/Astra Zeneca R&D in Sweden, the UK and Japan and additional positions at Orion Pharma in Finland and is currently a consultant at SDS Life Science, a Cytel company.
MSc Health Economics & Policy, BS Chemistry, BS Biological Sciences. Jo Annah Jensen has 21 years of experience within industry and the public health sector working across 46 indications as a market access, health economics & outcomes research (HE&OR) and real world evidence (RWE) lead.
Oncorena continues to build an organization with the necessary skills and experience in drug development as well as a broad and global experience from the pharmaceutical industry that is required to successfully develop and commercialize the Company’s drug candidate for breakthrough treatment of kidney cancer.